Published :
Tables : 55
Figures : 45
Category : Healthcare
No. of Pages : 180
Report Code : HC-1318
Gynecology Drugs Market is estimated to value over USD 93 billion by 2027 end and register a CAGR of over 5.5% during the forecast period 2020 to 2027. Gynecological ailments represent a wide range of divergent medical conditions, which are pertaining to the reproductive system of the female body. As a result, gynecological illnesses have a variety of conditions concerning the functioning of the ovaries, uterus and appendages. There are certain gynecological drugs market trends that are being demonstrated over the past few years. It has been observed that the acceptance of gynecology drugs has been pushing the market. Shifts in the lifestyles of women worldwide has pushed for greater improvements in their healthcare needs. A growing consciousness about good health, nutrition and overall well-being, has contributed to the rise in the demand for innovative gynecological treatments. Such opportunities have created inroads for drug manufacturers to establish better gynecological therapeutics that would deliver positive efficacy as well as minimal side-effects. Moreover, attributes such as revitalized economic growth and a rise in the geriatric female population are projected to boost the gynecology drugs market size. Segmentation-wise, the market has been fragmented into therapeutics which is bifurcated into hormonal and non-hormonal therapy. The segment for non-hormonal therapy is anticipated to account for the largest market share during the forecast time frame, due to the latest product development, productive qualities in the products, as well as boost in the acceptance of such products. Furthermore, minimal usage of hormonal products owing to the risk of breast cancer has garnered considerable demand for pharmaceutical products that are non-hormonal. In the case of the indication segment, the market has been categorized based on various conditions ranging from menopausal disorder, gynecology cancers, contraception, gynecology infections, female infertility, polycystic ovary syndrome and others. Based on the type of distribution channel, the market has been divided into retail, hospital and online pharmacies. Market intelligence has predicted that online pharmacies are shown to prosper at a high CAGR in the forecast time span, since there is a preference for online pharmacies and a boost in the volume of people who use the internet. Key Market Players are F. Hoffmann-La Roche Ltd., Sanofi, Amgen Inc., GlaxoSmithKline plc, AstraZeneca, Pfizer, Inc., Lupin Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson, Bayer AG, Allergan Plc and Merck & Co. Gynecology Drugs Market Segmentation: By Therapeutics • Hormonal Therapy o Estrogen Therapy o Progestin Therapy o Combination Therapy o Thyroid Replacement Therapy o Parathyroid Hormone Therapy o Others • Non-hormonal Therapy o Anti-Infective Agents o Antineoplastic Agents o Anti-inflammatory Agents o Others By Indication • Gynecology Cancers • Endometriosis • Female Infertility • Menopausal Disorder • Gynecology Infections • Polycystic Ovary Syndrome • Contraception (Birth Control) • Others By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the gynecology drugs market by therapeutics, by indication, by distribution channel and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
Gynecological ailments represent a wide range of divergent medical conditions, which are pertaining to the reproductive system of the female body. As a result, gynecological illnesses have a variety of conditions concerning the functioning of the ovaries, uterus and appendages.
There are certain gynecological drugs market trends that are being demonstrated over the past few years. It has been observed that the acceptance of gynecology drugs has been pushing the market. Shifts in the lifestyles of women worldwide has pushed for greater improvements in their healthcare needs. A growing consciousness about good health, nutrition and overall well-being, has contributed to the rise in the demand for innovative gynecological treatments. Such opportunities have created inroads for drug manufacturers to establish better gynecological therapeutics that would deliver positive efficacy as well as minimal side-effects. Moreover, attributes such as revitalized economic growth and a rise in the geriatric female population are projected to boost the gynecology drugs market size.
Segmentation-wise, the market has been fragmented into therapeutics which is bifurcated into hormonal and non-hormonal therapy. The segment for non-hormonal therapy is anticipated to account for the largest market share during the forecast time frame, due to the latest product development, productive qualities in the products, as well as boost in the acceptance of such products. Furthermore, minimal usage of hormonal products owing to the risk of breast cancer has garnered considerable demand for pharmaceutical products that are non-hormonal.
In the case of the indication segment, the market has been categorized based on various conditions ranging from menopausal disorder, gynecology cancers, contraception, gynecology infections, female infertility, polycystic ovary syndrome and others.
Based on the type of distribution channel, the market has been divided into retail, hospital and online pharmacies. Market intelligence has predicted that online pharmacies are shown to prosper at a high CAGR in the forecast time span, since there is a preference for online pharmacies and a boost in the volume of people who use the internet.
Key Market Players are F. Hoffmann-La Roche Ltd., Sanofi, Amgen Inc., GlaxoSmithKline plc, AstraZeneca, Pfizer, Inc., Lupin Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson, Bayer AG, Allergan Plc and Merck & Co.
Gynecology Drugs Market Segmentation:
By Therapeutics
• Hormonal Therapy o Estrogen Therapy o Progestin Therapy o Combination Therapy o Thyroid Replacement Therapy o Parathyroid Hormone Therapy o Others • Non-hormonal Therapy o Anti-Infective Agents o Antineoplastic Agents o Anti-inflammatory Agents o Others
By Indication
• Gynecology Cancers • Endometriosis • Female Infertility • Menopausal Disorder • Gynecology Infections • Polycystic Ovary Syndrome • Contraception (Birth Control) • Others
By Distribution Channel
• Hospital Pharmacies • Retail Pharmacies • Online Pharmacies
By Region
• North America • Europe • Asia Pacific • Latin America • Middle East & Africa
FutureWise Key Takeaways:
Objectives of the Study:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Gynecology Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Gynecology Drugs Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Gynecology Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Gynecology Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Gynecology Drugs Market, By Indication Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Gynecology Cancers 7.2. Endometriosis 7.3. Female Infertility 7.4. Menopausal Disorder 7.5. Gynecology Infections 7.6. Polycystic Ovary Syndrome 7.7. Contraception (Birth Control) 7.8. Others 8. Global Gynecology Drugs Market, By Therapeutics Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Hormonal Therapy 8.1.1.Estrogen Therapy 8.1.2.Progestin Therapy 8.1.3.Combination Therapy 8.1.4.Thyroid Replacement Therapy 8.1.5.Parathyroid Hormone Therapy 8.1.6.Others 8.2.Non-hormonal Therapy 8.2.1.Anti-Infective Agents 8.2.2. Antineoplastic Agents 8.2.3.Anti-inflammatory Agents 8.2.4.Others 9. Global Gynecology Drugs Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Hospital Pharmacy 9.2. Retail Pharmacy 9.3. Online Pharmacy 10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2020-2027 11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4. Market Size (USD Million) Forecast for Latin America 2020-2027 12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Switzerland 12.2.9. Rest of Western Europe 12.3. Market Size (USD Million) Forecast for Europe 2020-2027 13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Japan 13.2.2. China 13.2.3. Singapore 13.2.4. India 13.2.5. Australia and New Zealand 13.2.6. ASEAN 13.2.7. South Korea 13.2.8. Taiwan 13.2.9. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Saudi Arabia 14.2.2. UAE 14.2.3. South Africa 14.2.4. Egypt 14.3. Market Size (USD Million) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. F. Hoffmann-La Roche Ltd. 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Sanofi 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Amgen Inc. 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. GlaxoSmithKline plc 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 AstraZeneca, Pfizer, Inc. 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Lupin Pharmaceuticals, Inc. 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Eli Lilly and Company 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Johnson & Johnson 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Bayer AG 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. Allergan Plc 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11. Merck & Co. 15.11.1. Company Overview 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 16. FutureWise SME Key Takeaway Points for Client
1. Market Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Scope
1.3.1. Years Considered for the Study
1.3.2. Market Covered
1.4. Currency
1.5. Limitations
1.6. Stakeholders
2. Research Methodology
2.1. Research Data
2.1.1. Secondary Data
2.1.1.1. Key Data from Secondary Sources
2.1.2. Primary Data
2.1.2.1. Key Data from Primary Sources
2.2. Market Size Estimation
2.3. Market Breakdown and Data Triangulation
2.4. Assumptions for the Study
3. Executive Summary
3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Global Gynecology Drugs Market Variables, Trends & Scope
4.1. Market Lineage Outlook
4.2. Penetration and Growth Prospect Mapping
4.3. Industry Value Chain Analysis
4.4. Cost Analysis Breakdown
4.5. Technology Overview
4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Global Gynecology Drugs Market Overview
5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Gynecology Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Gynecology Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Gynecology Drugs Market, By Indication Historical Analysis and Forecast 2020-2027 (USD Million)
7.1. Gynecology Cancers
7.2. Endometriosis
7.3. Female Infertility
7.4. Menopausal Disorder
7.5. Gynecology Infections
7.6. Polycystic Ovary Syndrome
7.7. Contraception (Birth Control)
7.8. Others
8. Global Gynecology Drugs Market, By Therapeutics Historical Analysis and Forecast 2020-2027 (USD Million)
8.1. Hormonal Therapy
8.1.1.Estrogen Therapy
8.1.2.Progestin Therapy
8.1.3.Combination Therapy
8.1.4.Thyroid Replacement Therapy
8.1.5.Parathyroid Hormone Therapy
8.1.6.Others
8.2.Non-hormonal Therapy
8.2.1.Anti-Infective Agents
8.2.2. Antineoplastic Agents
8.2.3.Anti-inflammatory Agents
8.2.4.Others
9. Global Gynecology Drugs Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million)
9.1. Hospital Pharmacy
9.2. Retail Pharmacy
9.3. Online Pharmacy
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
10.1. Introduction
10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
10.2.1. U.S.A
10.2.2. Canada
10.2.3. Mexico
10.3. Market Size (USD Million) Forecast for North America 2020-2027
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
11.1. Introduction
11.2. Regional Market Trends
11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
11.3.1. Brazil
11.3.2. Venezuela
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Market Size (USD Million) Forecast for Latin America 2020-2027
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
12.1. Introduction
12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
12.2.1. Germany
12.2.2. U.K
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Russia
12.2.7. Poland
12.2.8. Switzerland
12.2.9. Rest of Western Europe
12.3. Market Size (USD Million) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
13.1. Introduction
13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
13.2.1. Japan
13.2.2. China
13.2.3. Singapore
13.2.4. India
13.2.5. Australia and New Zealand
13.2.6. ASEAN
13.2.7. South Korea
13.2.8. Taiwan
13.2.9. Rest of Asia Pacific
13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
14.1. Introduction
14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
14.2.1. Saudi Arabia
14.2.2. UAE
14.2.3. South Africa
14.2.4. Egypt
14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
15.1. F. Hoffmann-La Roche Ltd.
15.1.1. Company Overview
15.1.2. Product Portfolio
15.1.3. SWOT Analysis
15.1.4. Financial Overview
15.1.5. Strategic Overview
15.2. Sanofi
15.2.1. Company Overview
15.2.2. Product Portfolio
15.2.3. SWOT Analysis
15.2.4. Financial Overview
15.2.5. Strategic Overview
15.3. Amgen Inc.
15.3.1. Company Overview
15.3.2. Product Portfolio
15.3.3. SWOT Analysis
15.3.4. Financial Overview
15.3.5. Strategic Overview
15.4. GlaxoSmithKline plc
15.4.1. Company Overview
15.4.2. Product Portfolio
15.4.3. SWOT Analysis
15.4.4. Financial Overview
15.4.5. Strategic Overview
15.5 AstraZeneca, Pfizer, Inc.
15.5.1. Company Overview
15.5.2. Product Portfolio
15.5.3. SWOT Analysis
15.5.4. Financial Overview
15.5.5. Strategic Overview
15.6 Lupin Pharmaceuticals, Inc.
15.6.1. Company Overview
15.6.2. Product Portfolio
15.6.3. SWOT Analysis
15.6.4. Financial Overview
15.6.5. Strategic Overview
15.7. Eli Lilly and Company
15.7.1. Company Overview
15.7.2. Product Portfolio
15.7.3. SWOT Analysis
15.7.4. Financial Overview
15.7.5. Strategic Overview
15.8. Johnson & Johnson
15.8.1. Company Overview
15.8.2. Product Portfolio
15.8.3. SWOT Analysis
15.8.4. Financial Overview
15.8.5. Strategic Overview
15.9. Bayer AG
15.9.1. Company Overview
15.9.2. Product Portfolio
15.9.3. SWOT Analysis
15.9.4. Financial Overview
15.9.5. Strategic Overview
15.10. Allergan Plc
15.10.1. Company Overview
15.10.2. Product Portfolio
15.10.3. SWOT Analysis
15.10.4. Financial Overview
15.10.5. Strategic Overview
15.11. Merck & Co.
15.11.1. Company Overview
15.11.2. Product Portfolio
15.11.3. SWOT Analysis
15.11.4. Financial Overview
15.11.5. Strategic Overview
16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics